NOUBAR AFEYAN
CIK 1222012 · last filed 2026-05-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$225.88M
Companies
17
Total Filings
178
Lifetime Open-Market Net
-$1.61B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MRNA | Director | 2,971,912 | $55.80 | $165.85M | -$1.65B | 95 | 2026-05-22 |
| FHTX | 10%+ Owner | 1,491,441 | $5.13 | $7.65M | $19.20M | 2 | 2024-05-24 |
| SANA | 10%+ Owner | 11,585,199 | $3.29 | $38.12M | $0 | 2 | 2024-02-14 |
| Omega Therapeutics, Inc. (OMGA) Delisted | Director | — | $0.14 | — | $0 | 3 | 2023-06-09 |
| Codiak BioSciences, Inc. (CDAK) Delisted | 10%+ Owner | 1,188,920 | $0.06 | $67.8K | $0 | 1 | 2022-09-16 |
| Rubius Therapeutics, Inc. (RUBY) Delisted | Director | — | $0.08 | — | $0 | 5 | 2022-05-13 |
| TMDX | 10%+ Owner | 0 | $76.29 | $0 | $0 | 1 | 2019-10-31 |
| MCRB | Director | 401,878 | $4.80 | $1.93M | $20.00M | 5 | 2019-06-20 |
| Evelo Biosciences, Inc. (EVLO) Delisted | Director | — | $0.00 | — | $0 | 1 | 2019-06-13 |
| QTRX | 10%+ Owner | 1,443,683 | $3.49 | $5.04M | $0 | 1 | 2017-12-13 |
| EDIT | 10%+ Owner | 2,786,967 | $2.62 | $7.30M | $0 | 1 | 2016-08-15 |
| BG Medicine, Inc. (BGMD) Delisted | Director | 485,002 | — | — | -$4.3K | 4 | 2014-12-05 |
| T2 Biosystems, Inc. (TTOO) Delisted | 10%+ Owner | 475 | $0.00 | $1 | $0 | 1 | 2014-08-14 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 1 | 2014-03-24 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | 1,542,616 | — | — | $300.0K | 1 | 2013-09-27 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | Director | 12,192,640 | — | — | $0 | 6 | 2009-09-22 |
| AGEN | Director | — | $6.60 | — | $0 | 3 | 2007-04-03 |
Recent Filings · Page 2 of 18
178 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-07-12 | MRNA | Sell (S) | −15,000 | -$1.76M | EDGAR |
| 2024-07-10 | MRNA | Notice (144) | −15,000 | -$1.74M | EDGAR |
| 2024-06-28 | MRNA | Sell (S) | −15,000 | -$1.91M | EDGAR |
| 2024-06-26 | MRNA | Notice (144) | −15,000 | -$2.06M | EDGAR |
| 2024-06-21 | MRNA | Sell (S) | −15,000 | -$2.00M | EDGAR |
| 2024-06-18 | MRNA | Notice (144) | −15,000 | -$2.07M | EDGAR |
| 2024-06-14 | MRNA | Sell (S) | −15,000 | -$2.21M | EDGAR |
| 2024-06-12 | MRNA | Notice (144) | −15,000 | -$2.23M | EDGAR |
| 2024-06-11 | MRNA | Notice (144) | −32,763 | -$4.86M | EDGAR |
| 2024-06-11 | MRNA | Notice (144) | −170,069 | -$25.23M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.